Merck (NYSE:MRK) has broken ground on a $1 billion facility in Wilmington, Delaware, becoming the latest pharmaceutical company to boost domestic investment as industry-targeted tariffs loom.

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Pharmaceutical giant Merck may build a $900 million manufacturing facility near Greenville. The state of Delaware has offered Merck a $30.2 million grant to encourage the company to choose the ...

Seven weeks after opening a new $1 billion vaccine manufacturing facility in North Carolina, Merck has revealed that it is breaking ground on another $1 billion plant—this one in Wilmington ...

April 29 (Reuters) - U.S. drugmaker Merck (MRK.N), opens new tab said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

First, it was Panasonic. Now, another major company is planting deeper roots in De Soto. Merck Animal Health has announced an expansion of its De Soto operations, and it’s bringing hundreds of ...

German pharmaceutical and specialty materials group Merck KGaA on Thursday guided more cautiously for 2025 earnings, citing foreign-exchange effects and uncertainty over tariffs.